TY - JOUR
T1 - Speech disorders in Parkinson's disease
T2 - pathophysiology, medical management and surgical approaches
AU - Dashtipour, Khashayar
AU - Tafreshi, Ali
AU - Lee, Jessica
AU - Crawley, Brianna
N1 - The prevalence of speech disorders among individuals with Parkinson's disease (PD) has been reported to be as high as 89%. Speech impairment in PD results from a combination of motor and nonmotor deficits. The production of speech depends upon the coordination of various motor activities: respiratio ...
PY - 2018/10/1
Y1 - 2018/10/1
N2 - The prevalence of speech disorders among individuals with Parkinson's disease (PD) has been reported to be as high as 89%. Speech impairment in PD results from a combination of motor and nonmotor deficits. The production of speech depends upon the coordination of various motor activities: respiration, phonation, articulation, resonance and prosody. A speech disorder is defined as impairment in any of its inter-related components. Despite the high prevalence of speech disorders in PD, only 3-4% receive speech treatment. Treatment modalities include pharmacological intervention, speech therapy, surgery, deep brain stimulation and vocal fold augmentation. Although management of Parkinsonian dysarthria is clinically challenging, speech treatment in PD should be part of a multidisciplinary approach to patient care in this disease.
AB - The prevalence of speech disorders among individuals with Parkinson's disease (PD) has been reported to be as high as 89%. Speech impairment in PD results from a combination of motor and nonmotor deficits. The production of speech depends upon the coordination of various motor activities: respiration, phonation, articulation, resonance and prosody. A speech disorder is defined as impairment in any of its inter-related components. Despite the high prevalence of speech disorders in PD, only 3-4% receive speech treatment. Treatment modalities include pharmacological intervention, speech therapy, surgery, deep brain stimulation and vocal fold augmentation. Although management of Parkinsonian dysarthria is clinically challenging, speech treatment in PD should be part of a multidisciplinary approach to patient care in this disease.
KW - Parkinson's disease
KW - dysarthria
KW - hypophonia
KW - levodopa
KW - speech
KW - therapy
KW - vocal fold augmentation
KW - voice
UR - http://www.scopus.com/inward/record.url?scp=85058745946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058745946&partnerID=8YFLogxK
U2 - 10.2217/nmt-2018-0021
DO - 10.2217/nmt-2018-0021
M3 - Review article
C2 - 30223711
SN - 1758-2032
VL - 8
SP - 337
EP - 348
JO - Neurodegenerative disease management
JF - Neurodegenerative disease management
IS - 5
ER -